kijiji 0
Woodland Farm Brewery celebrates 9 years of brewing in MarcyChapter 3: Embracing the Inner Child
In conclusion, the rise of the cute economy reflects a broader shift in consumer preferences towards products that evoke joy, individuality, and creativity. With its ability to tap into nostalgia, promote self-expression, and spark innovation, the cute economy has captured the hearts of young people and transformed the way we consume and interact with the world around us. As we continue to embrace all things adorable and whimsical, the future of the cute economy looks bright and promising.World Leaders Pay Tribute To Former US President Jimmy Carter
'Trust and reserve judgement' on rebrand, says Jaguar Jaguar A still from Jaguar's new advert which was shared on social media. Jaguar has urged people to "trust and reserve judgement" over the rebrand of the carmaker. The company, embarking on the biggest change in its 102-year old history, released a new logo and a so-called "social media tease" this week, ahead of its relaunch as an electric-only brand in early December. The teaser video has faced backlash, with many critics pointing to the fact it doesn't feature an actual car. Others have praised the company for being bold and shaking things up. Either way, the rebrand has grabbed people's attention and Jaguar has since admitted it not only expected such debate - but it wanted it. In the 1960s, Jaguar launched the E-Type and XJ which have come to be known among some of the most iconic cars of all time. Now the company is trying to do the same again by unveiling its new "design vision" in Miami next month. Teasing the vision online, the 30 second advert features models in extravagant, brightly-coloured outfits who reveal the new company logo written as JaGUar. No cars, no suave men in suits, no big cats. "Do you sell cars?" was the response on X, from owner Elon Musk, who is also the boss of electric car firm Tesla. "This is surely a joke?" added one user, while another suggested the move would "cost jobs and do real damage". Some said "Go woke, go broke". Jaguar/PA Specsavers, known for its humorous social media manner, created a mock-up of its own logo in response, which looked like it had been created on Microsoft Paint. While supermarket Aldi chipped in at Jaguar's "Copy Nothing" slogan with: "You sound like our legal team." Amid the anger and sarcasm, Jaguar has doubled down on its decision, replying to some posts with... Michael RaceThe ex-distribution date for all Open-End Funds is December 27, 2024. The ex-distribution date for all closed-end funds is December 31, 2024. Estimated December 2024 Distributions for Purpose USD Cash Management Fund, Purpose Cash Management Fund, Purpose High Interest Savings Fund, and Purpose US Cash Fund The December 2024 distribution rates for Purpose USD Cash Management Fund, Purpose Cash Management Fund, Purpose High Interest Savings Fund, and Purpose US Cash Fund are estimated to be as follows: Purpose expects to issue a press release on or about December 27, 2024, which will provide the final distribution rate for Purpose USD Cash Management Fund, Purpose Cash Management Fund, Purpose High Interest Savings Fund, and Purpose US Cash Fund. The ex-distribution date will be December 30, 2024. About Purpose Investments Inc. Purpose Investments is an asset management company with more than $23 billion in assets under management. Purpose Investments has an unrelenting focus on client-centric innovation and offers a range of managed and quantitative investment products. Purpose Investments is led by well-known entrepreneur Som Seif and is a division of Purpose Unlimited, an independent technology-driven financial services company. For further information, please contact: Keera Hart ... 905-580-1257 Commissions, trailing commissions, management fees and expenses all may be associated with investment fund investments. Please read the prospectus and other disclosure documents before investing. Investment funds are not covered by the Canada Deposit Insurance Corporation or any other government deposit insurer. There can be no assurance that the full amount of your investment in a fund will be returned to you. If the securities are purchased or sold on a stock exchange, you may pay more or receive less than the current net asset value. Investment funds are not guaranteed, their values change frequently and past performance may not be repeated. MENAFN17122024004107003653ID1109004929 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.
Editor's take: Samsung faces the challenge of balancing improvements in its foundry business with the demands of its smartphone division. The company's ability to navigate these complexities will be crucial for maintaining its leadership in both the semiconductor and smartphone markets. Samsung Foundry has once again failed to secure a contract from Qualcomm for the production of its latest flagship mobile processor, the Snapdragon 8 Elite Gen 2. This setback marks another chapter in Samsung's ongoing struggle to compete with industry leader TSMC, which has been awarded the entire manufacturing contract for the upcoming chip. The decision comes at a critical juncture for Samsung Foundry, which has been grappling with low yield rates in recent months. However, there are signs of improvement on the horizon. The company recently stabilized its 3nm production process, achieving acceptable yield rates, and is simultaneously pushing forward with the development of even more advanced 2nm chips. Samsung also has ambitious plans to produce 1.4nm chips by 2027. Despite these advancements, Qualcomm's choice to partner exclusively with TSMC for the Snapdragon 8 Elite Gen 2 reflects the current state of the industry. TSMC's proven track record and reliability likely outweighed any potential cost savings that Samsung might have offered. This decision is particularly impactful given the widespread adoption of Snapdragon SoCs in flagship smartphones. The loss of this contract doesn't spell the end for Samsung Foundry's aspirations. The company is expected to make another bid for the production of the Snapdragon 8 Elite Gen 3 when it enters development. To improve its chances, Samsung will need to successfully fulfill orders from other clients and further improve yield rates. This development coincides with reports of a significant price increase for the Snapdragon 8 Elite Gen 2, which could lead to higher costs for premium smartphones, including Samsung's Galaxy series. This situation presents a dilemma for Samsung's mobile division as it may need to consider alternative strategies to maintain competitive pricing. One potential solution could involve reviving Samsung's in-house Exynos chip line for future Galaxy devices, such as the S26 series. This move could help offset the impact of rising Snapdragon prices. Alternatively, Samsung might explore partnerships with other chip manufacturers like MediaTek or make compromises in other components such as displays and cameras to offset increased processor costs. Despite these challenges, industry experts anticipate that Samsung's upcoming Galaxy S25 series will remain among the top smartphone choices in 2025. The company's strength in other areas of mobile technology should support its operations as it continues to refine its foundry capabilities and chip production processes.Report: W. Kentucky coach Tyson Helton extended through '28
Jimmy Carter, the 39th US president, has died at 100UCF, LSU face off with improved focus in mind
Kodiak Sciences (NASDAQ:KOD) Stock Price Down 7.5% – Time to Sell?In a press conference held earlier today, Mbappe addressed the allegations head-on. The 22-year-old striker appeared composed and resolute as he categorically denied any wrongdoing. "I want to make it clear that these allegations are completely false and baseless," Mbappe stated. "I respect women and their boundaries, and I would never engage in such reprehensible behavior."
SGR-1505 is under clinical development by and currently in Phase I for Burkitt Lymphoma. According to GlobalData, Phase I drugs for Burkitt Lymphoma have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. SGR-1505 overview SGR-1505 is under development for the treatment of BTK-resistant, refractory or relapsed B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma (MCL), Waldenstrom macroglobulinemia, MALT lymphoma, follicular lymphoma, Burkitt lymphoma, plasmablastic lymphoma, high-grade B-cell lymphoma, primary cutaneous follicle center lymphoma, primary effusion lymphoma, primary mediastinal large B cell lymphoma, T-cell/histiocyte rich lymphoma, ALK-positive large B-cell lymphoma, primary cutaneous diffuse large B-cell lymphoma splenic marginal zone lymphoma, nodal marginal zone lymphoma, HHV8-positive DLBCL and duodenal-type follicular lymphoma. It is administered through oral route in the form of tablet. The drug candidate acts by oncogenic activation of nuclear factor-kappa B which acts by targeting MALT1 activity. It is developed based on the artificial intelligence (AI) technology. Schrodinger overview is a healthcare technology company that provides software solutions for drug discovery. The company offers a computational platform designed with predictive modeling, data analytics and collaboration applicable to molecular discovery. Its pipeline products include SGR-1505 (MALT1) against non-Hodgkin’s lymphoma, SGR-2921 (CDC7) to treat hematological cancers and solid tumors and SGR-3515 (Wee1) for gynecological cancers, and LRRK2 for Neurology and SOS1 for cancers and others. ‘s other products include small molecule products, biological drug discovery and material science products. It provides training, documentation and support services. The company operates through offices in the US, Germany, Japan, Ireland, the UK, India, China and South Korea. is headquartered in New York City, New York, the US. For a complete picture of SGR-1505’s drug-specific PTSR and LoA scores, This content was updated on 12 April 2024 From Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors. , the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s .A federal judge on Friday rejected the US Securities and Exchange Commission's request to sanction Elon Musk after he failed to appear for court-ordered testimony for the regulator's probe into his $44-billion takeover of Twitter. US District Judge Jacqueline Scott Corley in San Francisco said sanctions over Musk's 10 September absence were unnecessary, after the world's richest person testified on 3 October and agreed to pay the SEC's $2 923 of travel costs. READ | 'Backdoor control': Elon Musk blasts Australia's proposed ban on social media for children "Because the present circumstances forestall any occasion for meaningful relief that the court could grant, the SEC's request is moot," Corley wrote. The SEC had sought a declaration that Musk violated a 31 May court order to provide... news24
Former US President Jimmy Carter dies – He was 100 years oldSherritt International Co. ( OTCMKTS:SHERF – Get Free Report ) was the recipient of a significant decrease in short interest in the month of December. As of December 15th, there was short interest totalling 238,300 shares, a decrease of 21.7% from the November 30th total of 304,300 shares. Based on an average daily trading volume, of 1,900 shares, the days-to-cover ratio is currently 125.4 days. Sherritt International Stock Performance Shares of SHERF opened at $0.11 on Friday. The stock’s 50-day moving average price is $0.12 and its two-hundred day moving average price is $0.15. Sherritt International has a 1 year low of $0.07 and a 1 year high of $0.27. About Sherritt International ( Get Free Report ) Featured Stories Receive News & Ratings for Sherritt International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sherritt International and related companies with MarketBeat.com's FREE daily email newsletter .
The concept of "not being pushy" in Douyin e-commerce is gaining traction as brands and influencers realize the importance of building genuine connections with their audience. While the platform offers ample opportunities for reaching a large number of consumers quickly, bombarding users with constant promotional content can lead to viewer fatigue and a decline in trust. Instead, brands are now focusing on providing valuable and entertaining content that resonates with their target audience, fostering a sense of community and loyalty.In conclusion, the dispute over casualty figures in the Russia-Ukraine conflict highlights the complexities and challenges of assessing the human cost of war. Accurate and verified data are essential for understanding the true impact of the conflict and guiding efforts towards peace and reconciliation. As the international community navigates through these contentious issues, a commitment to transparency, truth, and compassion must guide our collective response to the crisis in Ukraine.